Surepost regulatory update

Dainippon submitted an application to Japan's Ministry of Health, Labor and Welfare (MHLW) to expand the label for Type II diabetes drug Surepost repaglinide tablets to include combination therapy with thiazolidinediones and with biguanides. Dainippon markets the short-acting beta cell stimulating meglitinide as combination therapy with alpha-glucosidase inhibitors and as monotherapy. Dainippon said it is in Phase III testing in Japan for Surepost in combination with dipeptidyl peptidase-4 (DPP-4) inhibitors. ...